Skip to main content
Log in

Rapid response and sustained remission by rituximab in four cases of plasma-exchange-failed acute thrombotic thrombocytopenic purpura

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Kremer Hovinga JA, Meyer SC. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol. 2008;15(5):445–50. doi:10.1097/MOH.0b013e328309ec62.

    Article  PubMed  Google Scholar 

  2. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11–8. doi:10.1182/blood-2008-02-078170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28(3):385–91. doi:10.1006/bcmd.2002.0522.

    Article  PubMed  Google Scholar 

  4. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71(2):105–8. doi:10.1002/ajh.10204.

    Article  CAS  PubMed  Google Scholar 

  5. Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizashi H, Fujimura Y, et al. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol. 2005;81(5):433–6. doi:10.1532/IJH97.04187.

    Article  PubMed  Google Scholar 

  6. Rüfer A, Brodmann D, Gregor M, Kremer Hovinga JA, Lämmle B, Wuillemin WA. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly. 2007;137(37–38):518–24.

    PubMed  Google Scholar 

  7. Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher. 2008;23(5):151–6. doi:10.1002/jca.20172.

    Article  PubMed  Google Scholar 

  8. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451–61. doi:10.1111/j.1365-2141.2006.06448.x.

    Article  CAS  PubMed  Google Scholar 

  9. Cataland SR, Wu HM. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura. Expert Opin Pharmacother. 2007;8(4):437–44. doi:10.1517/14656566.8.4.437.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pasquale Niscola.

About this article

Cite this article

Scaramucci, L., Niscola, P., Palumbo, R. et al. Rapid response and sustained remission by rituximab in four cases of plasma-exchange-failed acute thrombotic thrombocytopenic purpura. Int J Hematol 89, 398–399 (2009). https://doi.org/10.1007/s12185-009-0274-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-009-0274-9

Keywords

Navigation